← Back to Screener
Theravance Biopharma, Inc. (TBPH)
Price$16.72
Favorite Metrics
Price vs S&P 500 (26W)13.23%
Price vs S&P 500 (4W)5.22%
Market Capitalization$877.44M
P/E Ratio (Annual)8.29x
All Metrics
Book Value / Share (Quarterly)$5.86
P/TBV (Annual)1.18x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)27.95%
Cash Flow / Share (Quarterly)$4.80
Price vs S&P 500 (YTD)-14.57%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)98.54%
EPS (TTM)$2.03
10-Day Avg Trading Volume0.39M
EPS Excl Extra (TTM)$2.03
Revenue Growth (5Y)8.37%
EPS (Annual)$2.06
ROI (Annual)35.69%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)250.84%
Cash / Share (Quarterly)$6.22
P/E Basic Excl Extra (TTM)8.29x
Revenue Growth QoQ (YoY)144.70%
P/E Normalized (Annual)8.29x
ROA (Last FY)21.81%
Revenue Growth TTM (YoY)66.92%
EBITD / Share (TTM)$0.93
ROE (5Y Avg)-14.54%
Operating Margin (TTM)43.18%
Cash Flow / Share (Annual)$-0.24
P/B Ratio2.96x
P/B Ratio (Quarterly)3.20x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)5.23x
Net Interest Coverage (TTM)-34.84x
ROA (TTM)25.35%
EV / EBITDA (TTM)11.80x
EPS Incl Extra (Annual)$2.06
Current Ratio (Annual)10.93x
Quick Ratio (Quarterly)10.73x
3-Month Avg Trading Volume0.58M
52-Week Price Return93.97%
P/E Incl Extra (TTM)8.29x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$4.84
P/S Ratio (Annual)8.16x
Asset Turnover (Annual)0.22x
52-Week High$21.03
Operating Margin (5Y Avg)-155.74%
EPS Excl Extra (Annual)$2.06
CapEx CAGR (5Y)-36.36%
Tangible BV CAGR (5Y)30.85%
26-Week Price Return20.11%
Quick Ratio (Annual)10.73x
13-Week Price Return-16.86%
Total Debt / Equity (Annual)0.17x
Current Ratio (Quarterly)10.93x
Enterprise Value$562.082
Revenue / Share Growth (5Y)12.57%
Asset Turnover (TTM)0.26x
Book Value / Share Growth (5Y)-2.47%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.08x
Pretax Margin (Annual)120.27%
Cash / Share (Annual)$6.22
3-Month Return Std Dev62.46%
Gross Margin (5Y Avg)88.64%
Net Income / Employee (TTM)$1
ROE (Last FY)35.69%
Net Interest Coverage (Annual)-2.11x
EPS Basic Excl Extra (Annual)$2.06
Receivables Turnover (TTM)3.36x
EV / Free Cash Flow (TTM)2.31x
Total Debt / Equity (Quarterly)0.14x
EPS Incl Extra (TTM)$2.03
Receivables Turnover (Annual)3.36x
ROI (TTM)41.73%
P/S Ratio (TTM)8.16x
Pretax Margin (5Y Avg)-139.06%
Revenue / Share (Annual)$2.09
Tangible BV / Share (Annual)$6.77
Forward P/E6.57x
Price vs S&P 500 (52W)59.33%
P/E Ratio (TTM)8.29x
Year-to-Date Return-10.64%
5-Day Price Return0.72%
EPS Normalized (Annual)$2.06
ROA (5Y Avg)16.36%
Net Profit Margin (Annual)98.54%
Month-to-Date Return3.02%
Cash Flow / Share (TTM)$-0.98
EBITD / Share (Annual)$0.90
EPS Growth (3Y)-44.23%
Operating Margin (Annual)43.18%
LT Debt / Equity (Annual)0.17x
P/CF (TTM)3.60x
ROI (5Y Avg)19.71%
P/E Excl Extra (TTM)8.29x
LT Debt / Equity (Quarterly)0.14x
EPS Basic Excl Extra (TTM)$2.03
P/TBV (Quarterly)2.12x
P/B Ratio (Annual)3.20x
Inventory Turnover (TTM)0.08x
Pretax Margin (TTM)120.27%
Book Value / Share (Annual)$5.86
Price vs S&P 500 (13W)-19.24%
Beta0.19x
Revenue / Share (TTM)$2.03
ROE (TTM)46.03%
52-Week Low$8.33
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
3.85
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TBPHTheravance Biopharma, Inc. | 8.16x | 66.92% | 100.00% | — | $16.72 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Theravance Biopharma is a biopharmaceutical company developing organ-selective small-molecule medicines for inflammation and immunology, with a focus on lung-selective drugs for respiratory disease. The company's approach aims to improve the therapeutic index by maximizing efficacy while minimizing systemic side effects. Its portfolio includes YUPELRI (revefenacin), an FDA-approved inhalation solution for COPD maintenance treatment.